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Abstract
miRNAs (microRNAs) are important regulators of gene expression. In higher eukaryotes, the tightly
controlled expression of different miRNAs, each of which regulates multiple target mRNAs, is crucial for
the maintenance of tissue type and the control of differentiation. miR-122 is a highly liver-specific miRNA
that is important in hepatitis C virus infection, cholesterol metabolism and hepatocellular carcinoma. In the
present review, we discuss the effects of miR-122 on liver physiology and pathology. Recent evidence of
pathways involved in the regulation of miR-122 expression is also considered.
Introduction
miRNAs (microRNAs) were first identified in Caenorhab-
ditis elegans when a gene involved in the heterochronic
pathway, lin-4, was shown to express a short non-coding
RNA product instead of a protein [1]. Subsequently, many
different miRNA molecules have been found in a broad range
of eukaryotes [2]. miRNAs are encoded in the genome and
are transcribed, usually by RNA polymerase II, within long
pri-miRNA (primary miRNA transcript) hairpins (Figure 1).
miRNAs may be encoded individually or as part of a cluster,
often with related targets, and pri-miRNAs may be unique
transcripts or introns of coding mRNAs [3]. Pri-miRNAs
undergo successive nuclear and cytoplasmic processing by
the RNAse III enzymes Drosha and Dicer respectively
(Figure 1). The resulting mature 21–23-nt single-stranded
miRNA molecule is incorporated into an active protein
complex, usually known as the miRISC (miRNA-induced
silencing complex) (Figure 1), as it shows much similarity to
the RISC (RNA-induced silencing complex) that mediates
siRNA (short interfering RNA) activity [3]. In animals,
miRNAs generally regulate the expression of specific genes
by binding with imperfect complementarity to sites in the 3′-
UTR (untranslated region) of target mRNAs. Each miRNA
has multiple target mRNAs, and an individual mRNA may
be targeted by multiple miRNAs. miRNA binding results in
repression of protein synthesis and in mRNA degradation,
with both effects observed to different extents in different
experimental systems. The mechanism behind this is not yet
fully understood [4].
Many miRNAs show specific expression patterns that are
governed by both tissue type and developmental stage. A
particularly striking example of this regulation is miR-122,
which was first identified when miRNAs were isolated from
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several different mouse tissues. miR-122 accounted for 72 %
of all the miRNAs cloned from the liver, and was not detected
in any of the other tissues analysed [5]. miR-122 levels in
the liver increase during embryogenesis, reaching approx.
66 000 copies per cell in adult mouse liver, and 135 000 copies
per cell in primary human hepatocytes [6]. The sequence
of miR-122 is conserved from humans to zebrafish, and in
situ hybridization in zebrafish indicated that the liver-specific
expression pattern of miR-122 is also highly conserved [7].
miR-122 is expressed as a unique miRNA within a single
transcript, which is designated hcr [6].
The high-level expression of miR-122 in liver makes it
an attractive candidate for study, as it is likely to have
important roles in liver physiology. Identification of miR-
122 target genes demonstrated that it regulates significant liver
processes, particularly cholesterol metabolism [8,9]. miR-122
is also associated with disease and has a major positive role in
HCV (hepatitis C virus) infection [10], and a negative role in
HCC (hepatocellular carcinoma) [11]. Despite the extensive
effects of miR-122 on gene expression in the liver, inactivation
of this miRNA does not appear to be detrimental to liver
function in animals [8,9,12].
In the present review, we discuss the targets of miR-122
and its role in normal and diseased liver function, and the
pathways governing its expression.
Regulation of HCV by miR-122
HCV is a positive-sense single-stranded RNA virus that
infects approx. 3 % of the global population [13]. Chronic
HCV infection can lead to liver cirrhosis and eventually to
HCC. Development of an effective treatment has become a
major international endeavour [14].
miR-122 is required for HCV replication in cultured Huh7
human hepatocytes [9,15]. miR-122 is recruited directly to
two adjacent binding sites in the 5′-UTR of HCV RNA, and
this binding is responsible for enhanced viral RNA synthesis
[15]. Initial observations suggested that miR-122 does not
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Figure 1 miR-122 biogenesis
A schematic representation of miR-122 expression in the liver. Transcription of pri-miR-122 shows circadian regulation.
Mature miR-122 is modified by GLD-2, which adds a single adenine to the 3′-end to generate a more stable form of the
miRNA. miR-122 regulates various target mRNAs that are involved in cholesterol metabolism, maintenance of the adult liver
phenotype and the circadian cycle. Ago, Argonaute; miRISC, miRNA-induced silencing complex; Pol II, RNA polymerase II.
affect HCV protein synthesis, implying that the miRNA has
a stimulatory effect on viral RNA synthesis [9]. Subsequent
analysis has shown that miR-122 does, in fact, have a
positive effect on viral translation [16,17]. This translational
stimulation is not sufficient to explain the effect of miR-122
on viral replication, which led to the conclusion that miR-
122 regulates both HCV translation and a second stage in the
replication cycle [17]. This second stage remains unidentified,
but miR-122 does not affect HCV RNA synthesis either in
cells or in isolated replication complexes [18,19], raising the
possibility that RNA stability may be regulated.
The lack of a protective vaccine against HCV and poor
patient tolerance of and response to the established therapy
of PEGylated IFN (interferon) α combined with ribavirin
mean that there is an urgent need for better treatments to
be developed [14]. The positive effect of miR-122 on the
HCV life cycle implies that miR-122 inhibition could be
used as a novel approach in the treatment of HCV-infected
individuals. However, quantification of miR-122 and HCV
RNA in infected human liver suggests that the relationship
between the miRNA and the virus is more complex in tissue
than in cultured cells. miR-122 levels did not correlate with
viral load, and individuals with lower pre-treatment miR-122
levels tended to respond poorly to IFN therapy [20]. In Huh7
cells, miR-122 was found to be down-regulated in response
to IFNβ [21]. This was thought to be one of the antiviral
effects of IFN treatment, but it was shown subsequently
that PEGylated IFNα in humans and IFNα in mice do not
affect miR-122 levels [20]. Despite the lack of correlation
between miR-122 and HCV load in infected patients, a recent
animal study has provided exciting data to support miR-122
inhibition as an anti-HCV therapy. miR-122 sequestration
and inactivation using a complementary LNA (locked nucleic
acid) molecule had a potent antiviral effect in HCV-infected
chimpanzees [12]. This validates the principle of miR-122-
targeted HCV treatment, but clinical trials in humans will be
required before it can be established whether this approach
will bear fruit.
The endogenous targets of miR-122 and
its role in cholesterol metabolism
The first target of miR-122 to be identified was CAT-1
(cationic amino acid transporter 1) in the liver [6]. It
was shown subsequently that miR-122 repression of CAT-
1 synthesis is relieved under conditions of amino acid
starvation by the protein HuR binding to the CAT-1
C©The Authors Journal compilation C©2010 Biochemical Society
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3′-UTR [22]. It is not known whether any other miR-122
targets show similar complexity of regulation. Microarray
analysis following miR-122 inhibition in mice indicated
that miR-122 regulates hepatic fatty acid and cholesterol
synthesis, and controls plasma cholesterol levels [8,9]. It
was possible to identify direct miR-122 targets by looking
for mRNAs that show increased expression when miR-122
is sequestered and contain predicted miR-122 target sites
in the 3′-UTR [9]. Several such mRNAs were validated as
targets by testing the effects of miR-122 on luciferase–3′-
UTR reporters, and included mRNAs encoding proteins that
are usually repressed in hepatocytes, such as aldo-A (aldolase
A) and Ndrg3 (N-myc downstream regulated gene 3) [9].
This suggests that miR-122 plays a role in maintaining the
adult liver phenotype. The effects on cholesterol metabolism
are likely to be indirect, as mRNAs involved in cholesterol
biosynthesis tended to be down-regulated when miR-122 was
sequestered and to lack miR-122 seed matches [8,9].
A decline in plasma cholesterol levels alongside enhanced
fatty acid oxidation was observed in normal mice after
treatment with an antisense oligonucleotide against miR-
122 [8]. Additionally, miR-122 inhibition led to a decline
in plasma cholesterol levels and a significant improvement in
liver steatosis in a mouse obesity model [8]. No significant
side effects of miR-122 sequestration were observed in
mice or chimpanzees, supporting the potential of miR-
122 inhibition as a therapeutic target for metabolic disease
[8,9,12]. A specific reduction in damaging LDL (low-density
lipoprotein) cholesterol levels in chimpanzees treated with
miR-122 inhibitors is encouraging when considering this
approach as a treatment for hypercholesterolaemia [12].
miR-122 and cancer
It is well established that specific miRNAs play a significant
role in cancer [23]. A number of miRNAs are located in fragile
sites within the genome, and the dysregulation of miRNA
expression is a key factor in tumorigenesis [24]. Analysis
of the levels of specific miRNAs has also proved to be an
effective predictor of stage and treatment outcome in various
tumours [23].
A comparison of miR-122 levels in hepatocytes and
primary human HCC cells revealed that miR-122 is down-
regulated in HCC cells [11]. It was also shown that
reintroduction of miR-122 into HCC cells can reverse the
tumorigenic properties of these cells, whereas inhibition
of miR-122 in Huh-7 human hepatoma cells stimulates
the appearance of such properties [11,25]. This suggests
that miR-122 acts as a tumour suppressor in the liver. Some
miR-122 targets that may be involved in tumorigenesis have
been identified. Cyclin G1 is expressed at high levels in
a number of tumours, and miR-122 inhibits cyclin G1,
leading to improved sensitivity of HCC cells to the common
chemotherapeutic compound doxyrubicin [26]. Additionally,
it was shown that miR-122 acts as a tumour suppressor in the
liver by down-regulating expression of a protein commonly
associated with tumour metastasis, ADAM17 (a disintegrin
and metalloproteinase 17) [27].
These results suggest that miR-122-based therapeutic
strategies may be useful in the treatment of HCC. These
observations are also important when considering miR-122
inhibition as a therapy for HCV or hypercholesterolaemia.
No adverse effects were observed over the course of the
animal trials carried out to date [8,9,12,28], but a link
between low miR-122 levels and HCC implies that long-
term inactivation of the miRNA might be inadvisable,
and that it will be very important to follow up treated
animals for a long period after the treatment has ended. An
increased understanding of the association between miR-122
expression, HCV infection and HCC will be important for
clinical development of miR-122-based drugs.
miR-122 and the circadian rhythm
Circadian rhythms are mechanisms by which an organism
anticipates environmental rhythms and changes its physiolo-
gical or behavioural state accordingly [29]. The maintenance
of such rhythms, particularly in highly metabolic organs such
as the liver, is essential for normal function [30]. Specific
miRNAs have been identified as key players in regulation
and maintenance of circadian gene expression [31].
miR-122 expression and function have been shown to
be important in the circadian output of the liver [32].
Transcription of the miR-122 gene is circadian (Figure 1),
with pri- and pre-miR-122 levels fluctuating in a circadian
rhythm in mouse liver [32]. Mature miR-122 levels appear
to remain constant throughout the day, owing to the long
half-life and large steady-state pool of this miRNA. Despite
this, miR-122 depletion was linked to circadian changes in
expression of many mRNAs, some of which were shown to
be direct miR-122 targets [32]. The circadian transcription of
pri-miR-122 was found to be governed by the orphan nuclear
receptor REV-ERBα [32], but the question of how a constant
level of miR-122 can regulate fluctuating target levels remains
to be answered. It is possible there may be a specific role for
newly synthesized miR-122 in regulation of circadian targets,
or that functionally distinct subpopulations of miR-122 may
exist.
miR-122 3′-modification
miRNA expression can be regulated by changes in
transcription and processing, but modification of the mature
miRNA sequence may also affect its level or function.
There are a few specific examples of modification of animal
miRNAs, such as 3′-uridylation of certain miRNAs leading
to destabilization and loss of function [33]. miR-122 was
shown recently to be subject to post-synthesis modification
in the form of 3′-adenylation. This is catalysed by the
cytoplasmic GLD-2 poly(A) polymerase, which adds a single
adenine to the 3′-end of miR-122 (Figure 1). This results in
increased stability of miR-122, presumably by impeding a
3′-end-dependent degradation process [34]. Non-templated
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3′-adenines have also been detected on various other
miRNAs, but the functional consequences for these miRNAs
remain unclear [33].
Conclusions
The high expression of miR-122 in the liver appears to
correlate with a central role in various functions of normal
and diseased livers. It provides a very attractive target for
treatment of HCV and hypercholesterolaemia, and can be
effectively sequestered in vivo using antisense oligonuc-
leotides. Rather surprisingly, given the high intracellular
levels and numerous targets of miR-122, inactivation of
the miRNA does not have any apparent adverse effects
on liver physiology. However, reduced miR-122 expression
does show an association with hepatocellular carcinoma, and
further work will be necessary before any anti-miR-122-
based therapies can be administered to human patients.
miR-122 has several unusual functions that make it a useful
miRNA to study that is likely to provide insight into miRNA
mechanisms in general. The positive regulation that miR-122
exerts by binding to HCV RNA is only partially understood,
but shows that animal miRNAs can modulate processes other
than post-transcriptional repression of gene expression by
binding to 3′-UTR targets. The relief of miR-122-imposed
repression of CAT-1 by HuR binding is also an important
example of regulated miRNA activity. The regulation of miR-
122 activity by circadian transcription, despite maintenance
of miR-122 levels, suggests that it may be wrong to assume
that miRNA quantification provides an accurate indication
of the functional pool. A more detailed insight into all of
these processes will be important for our understanding of
liver biology and the regulation and mechanism of miRNAs.
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